The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. 2010

N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
Department of Radiation Oncology, Cerrahpasa Medical School, Istanbul University, 34098, Cerrahpasa, Istanbul, Turkey. nuranbese@superonline.com

There are no data regarding the late toxicity of trastuzumab (T) administration with radiotherapy (RT). In this experimental study, we aimed to asses if concurrent or sequential administration of T has any impact for the development of radiation-induced pulmonary fibrosis in rats. Fifty-four female Wistar-albino rats were divided into 6 groups. First group of rats (Group 1; concurrent T) had irradiation to whole thoracic region concurrently with T. Second group (Group 2: sequential T-RT) received thoracic irradiation, 1 week after T. Third group (Group 3: sequential RT-T) had thoracic irradiation first and they had T injection 1 week after RT. Fourth group (Group 4: T only) had only T application. Fifth group (Group 5: RT) had only RT. The last group (Group 6: sham) of rats were observed without any application. A single dose of 12 Gy was given to both lungs with an anterior field at 2 cm depth. T dose which was equivalent to 6 mg/kg adult dose was calculated for each rat, and injected by the tail vein. As an end point the extent of pulmonary fibrosis for each field was graded on a scale from 0 (normal lung or minimal fibrous thickening) to 4 (total fibrous obliteration of the field) at histopathological examination. The mean value of fibrosis scores were 1.44, 1.77, 1.75 and 1.62 for Group 1, 2, 3 and 5, respectively, without any statistically significant differences among them (P>0.05). The mean value of fibrosis scores for Group 4 and 6 were 0.25 and 0.33, respectively (P>0.05). When the mean value of fibrosis scores of the groups which had RT with or without T, compared with the observation and the T only groups, the difference was significant (P<0.05) (one-way ANOVA and Tukey HSD post hoc tests) As a conclusion: addition of T to thoracic irradiation either sequentially or concomitantly did not increase radiation-induced pulmonary fibrosis in rats.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D011833 Radiation Injuries, Experimental Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals. Experimental Radiation Injuries,Injuries, Experimental Radiation,Experimental Radiation Injury,Radiation Injury, Experimental
D005260 Female Females
D000068878 Trastuzumab A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. Trastuzumab beta,Trastuzumab-qyyp,Trazimera,Herceptin,Trastuzumab qyyp,beta, Trastuzumab
D000090324 Tumor Protein, Translationally-Controlled 1 A highly expressed protein in tumor cells, encoded by Tpt1 gene. It's involved in various cellular activities including protein synthesis, calcium-binding, MICROTUBULE stabilization, growth, and cell survival. Also, Tpt1 identified as a direct target gene of P53 tumor suppression. Histamine Releasing Factor,Histamine Releasing Factor, Lymphocyte-Dependent,Histamine-Releasing Factor (IgE-Dependent),Protein P23, Ehrlich Ascites Tumor,TPT1 Protein,Translationally-Controlled Tumor Protein,Factor, Histamine Releasing,Histamine Releasing Factor, Lymphocyte Dependent,Protein, TPT1,Protein, Translationally-Controlled Tumor,Translationally Controlled Tumor Protein,Tumor Protein, Translationally Controlled 1,Tumor Protein, Translationally-Controlled
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
January 2016, In vivo (Athens, Greece),
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
August 2016, Breast (Edinburgh, Scotland),
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
January 2020, Frontiers in medicine,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
February 2014, Medical science monitor : international medical journal of experimental and clinical research,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
July 2020, Medicina (Kaunas, Lithuania),
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
October 1999, Zhonghua nei ke za zhi,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
January 2024, Current molecular medicine,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
November 2015, Radiation research,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
January 2016, Biomedical reports,
N S Bese, and C Umay, and S Serdengecti, and N Kepil, and N Sut, and T Altug, and A Ober
June 2020, International journal of radiation biology,
Copied contents to your clipboard!